Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Table of Contents

October 01, 1988; Volume 34,Issue 4
  • You have access
    Cloned muscarinic receptor subtypes expressed in A9 L cells differ in their coupling to electrical responses.
    S V Jones, J L Barker, N J Buckley, T I Bonner, R M Collins and M R Brann
    Molecular Pharmacology October 1988, 34 (4) 421-426;
  • You have access
    Forskolin alters acetylcholine receptor gating by a mechanism independent of adenylate cyclase activation.
    M M White
    Molecular Pharmacology October 1988, 34 (4) 427-430;
  • You have access
    Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro.
    Z Hao, D A Cooney, N R Hartman, C F Perno, A Fridland, A L DeVico, M G Sarngadharan, S Broder and D G Johns
    Molecular Pharmacology October 1988, 34 (4) 431-435;
  • You have access
    Photoaffinity labeling of opioid delta receptors with an iodinated azido-ligand: [125I][D-Thr2,pN3Phe4,Leu5]enkephalyl-Thr6.
    P Bochet, C Icard-Liepkalns, F Pasquini, C Garbay-Jaureguiberry, A Beaudet, B Roques and J Rossier
    Molecular Pharmacology October 1988, 34 (4) 436-443;
  • You have access
    Electron microscopic localization of the beta-adrenergic receptor using a ferritin-alprenolol probe.
    K H Muntz, T A Calianos, L M Buja, J T Willerson, M Bernatowicz, C J Homcy and R M Graham
    Molecular Pharmacology October 1988, 34 (4) 444-451;
  • You have access
    Transducin inhibition of light-dependent rhodopsin phosphorylation: evidence for beta gamma subunit interaction with rhodopsin.
    D J Kelleher and G L Johnson
    Molecular Pharmacology October 1988, 34 (4) 452-460;
  • You have access
    The epidermal growth factor- and interferon-independent effects of double-stranded RNA in A431 cells.
    M S Chapekar, M C Knode and R I Glazer
    Molecular Pharmacology October 1988, 34 (4) 461-466;
  • You have access
    DNA binding by epipodophyllotoxins and N-acyl anthracyclines: implications for mechanism of topoisomerase II inhibition.
    K C Chow, T L Macdonald and W E Ross
    Molecular Pharmacology October 1988, 34 (4) 467-473;
  • You have access
    Thymidylate synthase as a determinant of 5-fluoro-2'-deoxyuridine response in human colonic tumor cell lines.
    S H Berger and F G Berger
    Molecular Pharmacology October 1988, 34 (4) 474-479;
  • You have access
    A naturally occurring variation in thymidylate synthase structure is associated with a reduced response to 5-fluoro-2'-deoxyuridine in a human colon tumor cell line.
    S H Berger, K W Barbour and F G Berger
    Molecular Pharmacology October 1988, 34 (4) 480-484;
  • You have access
    Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase.
    W B Parker, A R Bapat, J X Shen, A J Townsend and Y C Cheng
    Molecular Pharmacology October 1988, 34 (4) 485-491;
  • You have access
    2-Bromo-(diglutathion-S-yl)hydroquinone nephrotoxicity: physiological, biochemical, and electrochemical determinants.
    T J Monks, R J Highet and S S Lau
    Molecular Pharmacology October 1988, 34 (4) 492-500;
  • You have access
    Regulation of adenosine kinase by adenosine analogs.
    B B Lin, M C Hurley and I H Fox
    Molecular Pharmacology October 1988, 34 (4) 501-505;
  • You have access
    Relaxation of vascular and tracheal smooth muscle by cyclic nucleotide analogs that preferentially activate purified cGMP-dependent protein kinase.
    S H Francis, B D Noblett, B W Todd, J N Wells and J D Corbin
    Molecular Pharmacology October 1988, 34 (4) 506-517;
  • You have access
    A monoclonal antibody specifically modulates dihydropyridine-sensitive calcium current in BC3H1 myocytes.
    J M Caffrey and M C Farach
    Molecular Pharmacology October 1988, 34 (4) 518-526;
  • You have access
    Differential inactivation and G protein reconstitution of subtypes of [3H]5-hydroxytryptamine binding sites in brain.
    C A Stratford, G L Tan, M W Hamblin and R D Ciaranello
    Molecular Pharmacology October 1988, 34 (4) 527-536;
  • You have access
    (R)-(-)-[77Br]4-bromo-2,5-dimethoxyamphetamine labels a novel 5-hydroxytryptamine binding site in brain membranes.
    S J Peroutka, A Hamik, M A Harrington, A J Hoffman, C A Mathis, P A Pierce and S S Wang
    Molecular Pharmacology October 1988, 34 (4) 537-542;
  • You have access
    Relationship between delta-9-tetrahydrocannabinol-induced arachidonic acid release and secretagogue-evoked phosphoinositide breakdown and Ca2+ mobilization of exocrine pancreas.
    A Chaudhry, R H Thompson, R P Rubin and S G Laychock
    Molecular Pharmacology October 1988, 34 (4) 543-548;
  • You have access
    Regulation of alpha-bungarotoxin sites in chromaffin cells in culture by nicotinic receptor ligands, K+, and cAMP.
    S Geertsen, R Afar, J M Trifaró and M Quik
    Molecular Pharmacology October 1988, 34 (4) 549-556;
  • You have access
    Modification of slow inactivation of single sodium channels by phenytoin in neuroblastoma cells.
    F N Quandt
    Molecular Pharmacology October 1988, 34 (4) 557-565;
  • You have access
    Comparative cytotoxic effects of N-acetyl-p-benzoquinone imine and two dimethylated analogues.
    M Rundgren, D J Porubek, P J Harvison, I A Cotgreave, P Moldéus and S D Nelson
    Molecular Pharmacology October 1988, 34 (4) 566-572;
  • You have access
    Evidence for the involvement of sulfhydryl compounds in the inhibition of cellular DNA synthesis by selenite.
    G D Frenkel and D Falvey
    Molecular Pharmacology October 1988, 34 (4) 573-577;
  • You have access
    Redox cycling of bleomycin-Fe(III) and DNA degradation by isolated NADH-cytochrome b5 reductase: involvement of cytochrome b5.
    I Mahmutoglu and H Kappus
    Molecular Pharmacology October 1988, 34 (4) 578-583;
  • You have access
    1,3-(2-Chloroethyl)-1-nitrosourea potentiates the toxicity of acetaminophen both in the phenobarbital-induced rat and in hepatocytes cultured from such animals.
    M E Kyle, D Nakae, A Serroni and J L Farber
    Molecular Pharmacology October 1988, 34 (4) 584-589;
  • You have access
    Subcellular localization of leukotriene D4 receptors in sheep tracheal smooth muscle.
    S Mong, G Chi-Rosso, D W Hay and S T Crooke
    Molecular Pharmacology October 1988, 34 (4) 590-596;
  • You have access
    Two sites of azo reduction in the monooxygenase system.
    F J Peterson, J L Holtzman, D Crankshaw and R P Mason
    Molecular Pharmacology October 1988, 34 (4) 597-603;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 34, Issue 4
1 Oct 1988
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics